// App-Quantinova.ai

: Cough Triggers and Symptoms Among Patients with Refractory or Unexplained Chronic Cough in Two Phase 3 Trials of the P2X3 Receptor Antagonist Gefapixant (COUGH-1 and COUGH-2)

Researchers

Presenter

  • Alyn Morice

Principal Investigators

  • Surinder Birring

  • Peter Dicpinigaitis

  • Lorcan McGarvey

  • Ian Pavord

  • Jaclyn Smith

  • Carmen La Rosa

  • Qing Li

  • Allison Martin Nguyen

  • Jonathan Schelfhout

  • Anjela Tzontcheva

  • David Muccino

Medical Centers

  • University of Hull

  • Kings College, London,

  • Jack D. Weiler Hospital

  • University of Oxford,

  • University of Manchester

  • Merck & Co., Inc.

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Gefapixant

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved